Given the absence of data regarding ADCS-ADL scores in previous Simufilam studies and considering that both scales are co-primary endpoints, the focus will be on the ADAS-cog13 for analysis.

Source: https://seekingalpha.com/article/4653050-cassava-sciences-likely-potential-opportunity-from-phase-3-readout-next-year?source=feed_all_articles

Since Simufilam does not reverse existing damage, the smaller reduction in p-tau levels aligns with expectations.

Source: https://seekingalpha.com/article/4653050-cassava-sciences-likely-potential-opportunity-from-phase-3-readout-next-year?source=feed_all_articles

The next catalyst arrives when Cassava provides data from a Cognition Maintenance Study ("CMS") of ~100 patients who continue vs discontinue Simufilam, following 1-year of open-label treatment.

Source: https://seekingalpha.com/article/4580155-cassava-sciences-now-we-wait-but-in-hope-or-expectation?source=feed_all_articles